Comparing a new eczema injection to Dupixent
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study compares a new injection (GS101) against an approved medicine (Dupixent) for people with moderate-to-severe eczema. The goal is to see if GS101 works as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had atopic dermatitis (eczema) for at least one year.
- Your eczema is moderate to severe – covering a large area and needing strong treatment.
- You are not allergic to the study drug or its ingredients, including dupilumab (Dupixent).
- You have not gotten a live vaccine in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new biologic medicine (GS101) against an approved treatment (Dupixent) for conditions like atopic dermatitis. It is looking for healthy volunteers to compare how the body processes each drug after an injection under the skin.
This trial tests if a new medication, QL2108, works as well as the approved drug Dupixent for adults with moderate-to-severe atopic dermatitis (eczema). You may be able to join if you've had eczema for at least a year and have active symptoms covering a large area of your body.
This study compares a new injectable medicine (IBI3027) to an approved one (Dupilumab) for people with moderate-to-severe eczema. If you join, you'll receive one of the two treatments to see if the new one works as well for reducing itching and skin symptoms.
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.